Carola Heneweer1,2, Jason P Holland3, Vadim Divilov3, Sean Carlin4, Jason S Lewis1,3. 1. Program in Molecular Pharmacology and Chemistry, Memorial Sloan-Kettering Cancer Center, New York, New York. 2. Department of Diagnostic Radiology, University Hospital Schleswig-Holstein, Kiel, Germany. 3. Radiochemistry Service, Department of Radiology, Memorial Sloan-Kettering Cancer Center, New York, New York. 4. Department of Medical Physics, Memorial Sloan-Kettering Cancer Center, New York, New York.
Abstract
UNLABELLED: Targeted nanoparticle-based technologies show increasing prevalence in radiotracer design. As a consequence, quantitative contribution of nonspecific accumulation in the target tissue, mainly governed by the enhanced permeability and retention (EPR) effect, becomes highly relevant for evaluating the specificity of these new agents. This study investigated the influence of different tumor phenotypes on the EPR effect, hypothesizing that a baseline level of uptake must be exceeded to visualize high and specific uptake of a targeted macromolecular radiotracer. METHODS: These preliminary studies use (89)Zr-labeled mouse serum albumin ((89)Zr-desferrioxamine-mAlb) as a model radiotracer to assess uptake and retention in 3 xenograft models of human prostate cancer (CWR22rv1, DU-145, and PC-3). Experiments include PET and contrast-enhanced ultrasound imaging to assess morphology, vascularization, and radiotracer uptake; temporal ex vivo biodistribution studies to quantify radiotracer uptake over time; and histologic and autoradiographic studies to evaluate the intra- and intertumoral distribution of (89)Zr-desferrioxamine-mAlb. RESULTS: Early uptake profiles show statistically significant but overall small differences in radiotracer uptake between different tumor phenotypes. By 20 h, nonspecific radiotracer uptake was found to be independent of tumor size and phenotype, reaching at least 5.0 percentage injected dose per gram in all 3 tumor models. CONCLUSION: These studies suggest that minimal differences in tumor uptake exist at early time points, dependent on the tumor type. However, these differences equalize over time, reaching around 5.0 percentage injected dose per gram at 20 h after injection. These data provide strong support for the introduction of mandatory experimental controls of future macromolecular or nanoparticle-based drugs, particularly regarding the development of targeted radiotracers.
UNLABELLED: Targeted nanoparticle-based technologies show increasing prevalence in radiotracer design. As a consequence, quantitative contribution of nonspecific accumulation in the target tissue, mainly governed by the enhanced permeability and retention (EPR) effect, becomes highly relevant for evaluating the specificity of these new agents. This study investigated the influence of different tumor phenotypes on the EPR effect, hypothesizing that a baseline level of uptake must be exceeded to visualize high and specific uptake of a targeted macromolecular radiotracer. METHODS: These preliminary studies use (89)Zr-labeled mouse serum albumin ((89)Zr-desferrioxamine-mAlb) as a model radiotracer to assess uptake and retention in 3 xenograft models of human prostate cancer (CWR22rv1, DU-145, and PC-3). Experiments include PET and contrast-enhanced ultrasound imaging to assess morphology, vascularization, and radiotracer uptake; temporal ex vivo biodistribution studies to quantify radiotracer uptake over time; and histologic and autoradiographic studies to evaluate the intra- and intertumoral distribution of (89)Zr-desferrioxamine-mAlb. RESULTS: Early uptake profiles show statistically significant but overall small differences in radiotracer uptake between different tumor phenotypes. By 20 h, nonspecific radiotracer uptake was found to be independent of tumor size and phenotype, reaching at least 5.0 percentage injected dose per gram in all 3 tumor models. CONCLUSION: These studies suggest that minimal differences in tumor uptake exist at early time points, dependent on the tumor type. However, these differences equalize over time, reaching around 5.0 percentage injected dose per gram at 20 h after injection. These data provide strong support for the introduction of mandatory experimental controls of future macromolecular or nanoparticle-based drugs, particularly regarding the development of targeted radiotracers.
Authors: Jonghan Kim; C L Bronson; William L Hayton; Michael D Radmacher; Derry C Roopenian; John M Robinson; Clark L Anderson Journal: Am J Physiol Gastrointest Liver Physiol Date: 2005-10-06 Impact factor: 4.052
Authors: Jason P Holland; Vadim Divilov; Neil H Bander; Peter M Smith-Jones; Steven M Larson; Jason S Lewis Journal: J Nucl Med Date: 2010-07-21 Impact factor: 10.057
Authors: Jason P Holland; Eloisi Caldas-Lopes; Vadim Divilov; Valerie A Longo; Tony Taldone; Danuta Zatorska; Gabriela Chiosis; Jason S Lewis Journal: PLoS One Date: 2010-01-25 Impact factor: 3.240
Authors: Kenneth J Pienta; Cory Abate-Shen; David B Agus; Ricardo M Attar; Leland W K Chung; Norman M Greenberg; William C Hahn; John T Isaacs; Nora M Navone; Donna M Peehl; Jonathon W Simons; David B Solit; Howard R Soule; Terry A VanDyke; Michael J Weber; Lily Wu; Robert L Vessella Journal: Prostate Date: 2008-05-01 Impact factor: 4.104
Authors: Jane J Keating; Jeffrey J Runge; Sunil Singhal; Sarah Nims; Ollin Venegas; Amy C Durham; Gary Swain; Shuming Nie; Philip S Low; David E Holt Journal: Cancer Date: 2016-11-07 Impact factor: 6.860
Authors: Jai Woong Seo; Lisa M Mahakian; Sarah Tam; Shengping Qin; Elizabeth S Ingham; Claude F Meares; Katherine W Ferrara Journal: Nucl Med Biol Date: 2014-09-28 Impact factor: 2.408
Authors: Andrew D Newton; Jarrod D Predina; Christopher J Corbett; Lydia G Frenzel-Sulyok; Leilei Xia; E James Petersson; Andrew Tsourkas; Shuming Nie; Edward J Delikatny; Sunil Singhal Journal: J Am Coll Surg Date: 2018-11-22 Impact factor: 6.113
Authors: Andrew D Newton; Jarrod D Predina; Lydia G Frenzel-Sulyok; Michael H Shin; Yiqing Wang; Sunil Singhal Journal: J Thorac Dis Date: 2018-07 Impact factor: 2.895
Authors: Jyoti Roy; Frank Kuo; Falguni Basuli; Mark R Williams; Karen Wong; Michael V Green; Jurgen Seidel; Stephen S Adler; Biying Xu; Peter L Choyke; Elaine M Jagoda Journal: Cancer Biother Radiopharm Date: 2019-02-15 Impact factor: 3.099
Authors: Brian M Zeglis; Kuntal K Sevak; Thomas Reiner; Priya Mohindra; Sean D Carlin; Pat Zanzonico; Ralph Weissleder; Jason S Lewis Journal: J Nucl Med Date: 2013-05-24 Impact factor: 10.057